5-Amino-1MQ Dosage and Side Effects: Oral vs Subcutaneous

Key takeaways

• There is no human 5-amino-1MQ dose. No person has taken it in a published study, and ClinicalTrials.gov lists no registered trial as of October 2026.
• The tested doses are mouse doses injected under the skin: about 34 mg per kilogram a day (three injections) for 11 days, and 10 or 32 mg per kilogram once a day for 30 days, where only 32 worked.
• Oral versus subcutaneous is not close in mice: only 3.5% of an oral dose reached the blood, the oral peak never reached the level that half-blocks the target enzyme, and an injection gave about 30 times the exposure.
• Scaled by body surface area, the effective mouse dose is roughly 180 to 190 mg a day by injection for a 70 kg adult. That is arithmetic, not a dose, and the 25 to 50 mg capsules sold online are not in the same range.
• Side effects in humans are unknown. In mice, the higher dose lowered immune cells, and a lab screen showed it blocks the antidepressant-target enzyme MAO-A.

The direct answer: no human dose of 5-amino-1MQ exists, oral or subcutaneous, because no human has been given it in a study. What exists are mouse doses of 10 to 34 mg per kilogram a day, injected under the skin for 11 days to 8 weeks, and mouse pharmacokinetics showing that swallowing it delivers very little. Our 5-amino-1MQ profile covers the biology and legal status; the AOD-9604 dosage page does the same exercise for the peptide sold next to it, and the tesofensine profile covers the third compound in this "fat-loss" aisle.

The studied doses, all of them in mice

Sources: (Neelakantan 2018); (Neelakantan 2019); (Babula 2024); (Dimet-Wiley 2024); (ClinicalTrials.gov 2026).

Two things stand out. The doses that worked were large and frequent: three injections a day in the first study, and in the 2024 obesity study a 10 mg/kg dose that did essentially nothing for weight next to a 32 mg/kg dose that did. And every effect came from injections: we found no published study in which 5-amino-1MQ given by mouth changed weight, fat, glucose or muscle in any animal.

Oral vs subcutaneous: what the mouse data show

The 2024 study measured blood levels after each route (Babula 2024):

The oral peak, 14.5 ng/mL, never reached the 78 ng/mL needed to inhibit half the enzyme, while injected doses stayed above it for about two to four hours. The authors attribute the poor oral result to limited absorption from the gut and heavy first-pass metabolism in the liver, not to the molecule dissolving badly. In plain terms: in mice, swallowing 5-amino-1MQ delivered a small fraction of the drug that produced the published results.

None of this has been measured in people. Human absorption could be better or worse. But the capsule market rests on the assumption that a small molecule must work by mouth, and the only data available say that in mice this one largely did not.

Our arithmetic, labeled as arithmetic

Doses do not transfer between species by body weight. The standard first estimate uses body surface area: divide a mouse dose in mg/kg by about 12.3, the ratio of the human factor (37) to the mouse factor (3) (Nair 2016). For a 70 kg adult:

These are injected-dose equivalents. Now the capsule: if a person absorbed 3.5% of a 50 mg capsule, as mice did, about 1.75 mg would reach the blood, roughly a hundredth of the injected figure for the effective mouse dose. That comparison assumes human absorption matches mice, which nobody has checked.

None of these numbers is a dose. In real drug development, the surface-area figure is calculated from the highest dose with no adverse effects in animal toxicology, divided by a further safety factor of 10 to pick a first human dose, and then escalated under monitoring (Nair 2016). For 5-amino-1MQ no formal toxicology study has been published and no first-in-human study has been run.

Seller capsules and injection 'protocols', as claims

There is no reconstitution example. FDA warned an outsourcing facility in January 2026 that products compounded with 5-Amino-1MQ were not eligible for the 503B exemptions, because the substance does not appear on the 503B bulks list and is not used to make a drug in shortage (FDA warning letter 2026); it is not on the 503A bulks list either, and our legal tracker explains why that leaves no legal source. The reconstitution calculator is for medications dispensed with a labeled concentration, and no legal 5-amino-1MQ vial has one.

Side effects: what is known and what is not

In humans: nothing. No one has recorded side effects of 5-amino-1MQ in people under observation. Reports on forums cannot be tied to the compound, the dose or what was actually in the product.

In mice: little at the doses used, with two signals (Neelakantan 2018); (Babula 2024):

The authors suggest part of the glucose benefit may itself come from MAO-A inhibition rather than NNMT, which would make the off-target effect part of how the drug works.

Theoretical concerns from the enzyme's biology. NNMT clears excess nicotinamide (vitamin B3) and consumes S-adenosylmethionine, the body's main methyl donor; it also helps regulate metabolism in fat, liver and cancer cells (Pissios 2017). Blocking it for months could shift methylation and nicotinamide handling in ways no study has looked at, and stacking it with NAD+ precursors pushes nicotinamide higher on top. The longest exposure in any published study is eight weeks of daily injections in old mice (Dimet-Wiley 2024).

Who should not use it. Since nobody can be advised to, the list is categorical: anyone pregnant, breastfeeding or trying to conceive; anyone taking antidepressants or other serotonergic drugs; anyone with a cancer history; anyone with liver disease.

Bottom line

A truthful 5-amino-1MQ dosage chart has an empty human row. Above it sit mouse doses of 10 to 34 mg per kilogram a day by injection, an oral route that delivered 3.5% of the drug in mice, and a side-effect profile that consists of an immune-cell drop and an off-target enzyme hit. The seller capsules match none of it. If the goal is fat loss, the 5-amino-1MQ profile explains why the evidence points to drugs a clinician can actually prescribe.

Frequently asked questions

+−What is the 5-amino-1MQ dosage per day?

There is no human daily dose, because no person has taken 5-amino-1MQ in a published or registered study. The tested daily doses are mouse doses given by injection under the skin: about 34 mg per kilogram split into three injections for 11 days, and 10 or 32 mg per kilogram once a day for 30 days, where only the higher dose worked. Capsule doses of 25 to 50 mg come from sellers, not studies.

+−What is the 5-amino-1MQ subcutaneous dosage?

In mice, effective subcutaneous doses were 20 mg per kilogram three times a day, or 32 mg per kilogram once a day; 10 mg per kilogram once a day did little. Scaled to a 70 kg adult by body surface area, the effective mouse dose works out to roughly 180 to 190 mg a day by injection. That is arithmetic to show the gap, not a dose: no human has been given it under study.

+−5-amino-1MQ oral vs injection: which works better?

In mice, injection by a wide margin. A 30 mg per kilogram oral dose reached a peak blood level of 14.5 ng/mL, below the 78 ng/mL needed to block half of the target enzyme, and only 3.5% of it reached the circulation. A smaller injected dose produced about 30 times the total exposure. Every published effect we found came from injections. There are no human absorption data for either route.

+−What are the side effects of 5-amino-1MQ?

Unknown in humans, because no one has been monitored taking it. In mice the first obesity study reported no observable adverse effects, but in a later study the higher dose cut lymphocytes by 31% and monocytes by 50%, and in a laboratory screen the compound blocked monoamine oxidase A, the enzyme targeted by older antidepressants, by 67%. NNMT also handles nicotinamide clearance and methyl-group balance, which makes long-term effects a genuine unknown.

+−Is there a 5-amino-1MQ injection protocol?

No protocol has been tested in humans. The injection schedules sold online, typically daily injections of a few milligrams to tens of milligrams for several weeks, were written by sellers. The only tested schedules are mouse schedules of one to three injections a day for 11 days to 8 weeks, at 10 to 34 mg per kilogram a day, and no human schedule has ever been tested.

+−Can you take 5-amino-1MQ with antidepressants?

That combination has never been studied, and there is a specific reason for caution: in a laboratory screen, 5-amino-1MQ inhibited monoamine oxidase A by 67%. MAO-A inhibitors can interact dangerously with SSRIs, SNRIs and other serotonergic drugs. Whether human doses reach concentrations that matter is unknown, which is not the same as safe.

+−Is 5-amino-1MQ a peptide?

No. It is a small molecule, 5-amino-1-methylquinolinium, with no amino acids. It is sold next to peptides by the same vendors and clinics. Being a small molecule is why capsules exist at all, but in mice it was poorly absorbed by mouth.

+−Can a doctor prescribe 5-amino-1MQ?

Not lawfully in the United States in 2026. It is not approved, not part of any approved drug, not on FDA's 503A bulks list, and in January 2026 FDA warned an outsourcing facility that 5-Amino-1MQ does not appear on the 503B bulks list either, so products made with it were not eligible for the compounding exemptions.

Sources

1. StudyNeelakantan H et al. Selective and membrane-permeable small molecule inhibitors of nicotinamide N-methyltransferase reverse high fat diet-induced obesity in mice. Biochem Pharmacol 2018;147:141-52. (2018)
2. StudyNeelakantan H et al. Small molecule nicotinamide N-methyltransferase inhibitor activates senescent muscle stem cells and improves regenerative capacity of aged skeletal muscle. Biochem Pharmacol 2019;163:481-92. (2019)
3. StudyBabula JJ, Bui D, Stevenson HL, Watowich SJ, Neelakantan H. Nicotinamide N-methyltransferase inhibition mitigates obesity-related metabolic dysfunction. Diabetes Obes Metab 2024;26:5272-82. (2024)
4. ReviewNair AB, Jacob S. A simple practice guide for dose conversion between animals and human. J Basic Clin Pharm 2016;7:27-31. (2016)
5. ReviewPissios P. Nicotinamide N-methyltransferase: more than a vitamin B3 clearance enzyme. Trends Endocrinol Metab 2017;28:340-53. (2017)
6. RegulatoryFDA. Warning letter to GenoGenix LLC (outsourcing facility, Boca Raton, Florida), January 20, 2026: compounding with bulk drug substances, including 5-Amino-1MQ and NAD+, that do not appear on the 503B bulks list. (2026)
7. StudyDimet-Wiley AL et al. Nicotinamide N-methyltransferase inhibition mimics and boosts exercise-mediated improvements in muscle function in aged mice. Sci Rep 2024;14:15554. (2024)
8. SourceClinicalTrials.gov. Searches for 5-amino-1-methylquinolinium, 5-amino-1MQ and NNMT inhibitor, run October 10, 2026: no registered studies. (2026)